Bristol-Myers/Nastech Stadol marketing agreement
Executive Summary
Nastech announced Jan. 21 that it has granted Bristol-Myers an exclusive license for use of its nasal delivery system with the analgesic agent, butorphanol. Bristol-Myers will market the drug and Nastech will receive a licensing fee and royalties.